JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB250092

Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal AKR1C1 antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Recombinant full length protein - Human samples. Cited in 1 publication.

View Alternative Names

DDH, DDH1, AKR1C1, Aldo-keto reductase family 1 member C1, 20alpha-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid 3-dehydrogenase, Chlordecone reductase homolog HAKRC, Dihydrodiol dehydrogenase 1, High-affinity hepatic bile acid-binding protein, 20-alpha-HSD, DD1, HBAB

5 Images
Flow Cytometry (Intracellular) - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)
  • Flow Cyt (Intra)

Supplier Data

Flow Cytometry (Intracellular) - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)

This data was developed using ab179448, the same antibody clone in a different buffer formulation.

Intracellular flow cytometric analysis of permeabilized U87-MG cells labeling AKR1C1/AKR1C2 with ab179448 at 1/10 dilution (red), compared to a rabbit IgG negative control (green).

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)

Immunocytochemical/immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized U-87 MG (human glioblastoma- astrocytoma epithelial cell) cells labelling AKR1C1/AKR1C2 with primary antibody anti-AKR1C1/AKR1C2 (ab179448) at 1/500 dilution, followed by AlexaFluor®488 Goat anti-Rabbit (ab150077) secondary antibody at 1/1000 dilution. Confocal image showing cytoplasmic and nuclear staining in U-87 MG cell line. Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) was used to counterstain tubulin at 1 : 200 dilution. The nuclear counter stain is DAPI (blue).

This data was developed using ab179448, the same antibody clone in a different buffer formulation.

Immunoprecipitation - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)
  • IP

Supplier Data

Immunoprecipitation - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)

AKR1C1/AKR1C2 was immunoprecipitated from U-87 MG lysates with ab179448 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab179448 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP) (ab131366) was used at 1/5000 dilution. Lane 1 : U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate 10 μg Lane 2 : ab179448 in U-87 MG (human glioblastoma-astrocytoma epithelial cell) whole cell lysate Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab179448 in U-87 MG whole cell lysate Blocking and dilution buffer and concentration : 5% NFDM/TBST.

All lanes:

Immunoprecipitation - Anti-AKR1C1/AKR1C2 antibody [EPR11542] (<a href='/en-us/products/primary-antibodies/akr1c1-akr1c2-antibody-epr11542-ab179448'>ab179448</a>) at 1/30 dilution

All lanes:

U-87 MG lysates

Secondary

All lanes:

Immunoprecipitation - VeriBlot for IP Detection Reagent (HRP) (<a href='/en-us/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution

false

Exposure time: 180s

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)
  • WB

Supplier Data

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)

Blocking buffer and concentration :  5% NFDM/TBST.  Diluting buffer and concentration :  5% NFDM/TBST. This data was developed using ab179448, the same antibody clone in a different buffer formulation.

All lanes:

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] (<a href='/en-us/products/primary-antibodies/akr1c1-akr1c2-antibody-epr11542-ab179448'>ab179448</a>) at 1/1000 dilution

Lane 1:

His-tagged human AKR1C1 recombinant protein, full-length

Lane 2:

His-tagged human AKR1C2 recombinant protein, full-length

Lane 3:

His-tagged human AKR1C3 recombinant protein, full-length

Lane 4:

His-tagged human AKR1C4 recombinant protein, full-length

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/20000 dilution

Observed band size: 39 kDa

false

Exposure time: 40s

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)
  • WB

Supplier Data

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] - BSA and Azide free (AB250092)

This data was developed using ab179448, the same antibody clone in a different buffer formulation.

All lanes:

Western blot - Anti-AKR1C1/AKR1C2 antibody [EPR11542] (<a href='/en-us/products/primary-antibodies/akr1c1-akr1c2-antibody-epr11542-ab179448'>ab179448</a>) at 1/1000 dilution

Lane 1:

HepG2 lysate at 10 µg

Lane 2:

U87-MG lysate at 10 µg

Lane 3:

Human fetal liver lysate at 10 µg

Lane 4:

HeLa lysate at 10 µg

Predicted band size: 37 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR11542

Isotype

IgG

Carrier free

Yes

Reacts with

Human

Applications

ICC/IF, Flow Cyt (Intra), IP, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

AKR1C1 and AKR1C2 (Swiss Prot: Q04828/P52895) sequences are 98% identical.

style
left-column

Complementary Products

Primary Antibodies

AB209899

Anti-AKR1C3+AKR1C4 antibody [EPR16726]

RabMAb|Recombinant|Trial Size

Immunocytochemistry/ Immunofluorescence - Anti-AKR1C3+AKR1C4 antibody [EPR16726] (AB209899)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB9485

Anti-GAPDH antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Immunocytochemistry/ Immunofluorescence - Anti-GAPDH antibody - Loading Control (AB9485)

  • 5
  • 88
Primary Antibodies

AB8227

Anti-beta Actin antibody - Loading Control

BOND RX™ Validated|Lab Essentials

Western blot - Anti-beta Actin antibody - Loading Control (AB8227)

  • 5
  • 104
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "FlowCytIntra" : {"fullname" : "Flow Cytometry (Intracellular)", "shortname":"Flow Cyt (Intra)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "FlowCytIntra-species-checked": "testedAndGuaranteed", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "<p></p>" }, "Recombinant full length protein - Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "FlowCytIntra-species-checked": "notRecommended", "FlowCytIntra-species-dilution-info": "", "FlowCytIntra-species-notes": "" } } }
style
left-column

Product details

ab250092 is the carrier-free version of ab179448.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.

Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

Compatibility
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Storage buffer
pH: 7.2 - 7.4 Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C
Storage information
Do Not Freeze
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The AKR1C1 and AKR1C2 are members of the aldo-keto reductase family. These enzymes also known as dihydrodiol dehydrogenases reduce a variety of substrates including steroids prostaglandins and xenobiotics. AKR1C1 has a molecular mass of approximately 37 kDa while AKR1C2 has a similar but slightly distinct mass. These proteins are expressed in various tissues including the liver prostate and mammary glands where they perform their enzymatic functions.
Biological function summary

The AKR1C1/AKR1C2 enzymes play significant roles in steroid hormone metabolism. They modulate the conversion of active hormones to their inactive forms and vice versa affecting the cellular concentration of these hormones. The proteins do not function as part of a larger complex but influence multiple biochemical processes through their enzymatic actions. Their roles in the regulation of sex steroids are important for maintaining normal cellular activity and tissue homeostasis.

Pathways

AKR1C1 and AKR1C2 are involved in intricate steroid hormone signaling and metabolism pathways. They engage with the androgen and estrogen receptor signaling pathways by modulating hormone availability. The interplay with enzymes like 5-alpha reductase and aromatase highlights their role in the balance of active and inactive hormone forms within these pathways. Their function can influence cellular proliferation and differentiation processes within different tissues.

AKR1C1/AKR1C2 have links to hormone-related cancers such as prostate and breast cancer. These enzymes impact the local hormone levels affecting cancer progression and response to therapy. Alterations in AKR1C1 and AKR1C2 expression or function can lead to hormone imbalances influencing cancer risk and treatment outcomes. Through their modulation of steroid hormones they connect to the activity of proteins like androgen and estrogen receptors which are critical in the pathogenesis of hormone-driven cancers.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Cytosolic aldo-keto reductase that catalyzes NADPH-dependent reduction of ketosteroids to hydroxysteroids. Displays broad substrate specificity with distinct positional and stereochemistry, primarily generating 20alpha-hydroxysteroids, but also 3alpha/beta- and 17beta-hydroxysteroids (PubMed : 10998348, PubMed : 11013348, PubMed : 14672942, PubMed : 19218247, PubMed : 11995921, PubMed : 12604236). Involved in neurosteroid metabolism. Reduces 5alpha-dihydrodeoxycorticosterone (5-alpha-DHDOC) to neuroactive steroid 3alpha,5alpha-tetrahydrodeoxycorticosterone (3alpha,5alpha-THDOC) known to alter neural excitability via allosteric activation of gamma-aminobutyric acid type A (GABAAR) receptors. Inactivates 3alpha-hydroxy-5alpha-pregnan-20-one (3alpha,5alpha-THP) into less potent neurosteroid 3alpha,20alpha-dihydroxy-5alpha-pregnane (PubMed : 11995921, PubMed : 12604236). Catalyzes the reduction of progesterone to less potent progestogen (20S)-hydroxypregn-4-en-3-one likely regulating ligand availability for progesterone receptors (PubMed : 10998348, PubMed : 11013348, PubMed : 12604236). In androgen catabolism, may predominantly act as a phase I enzyme by introducing a hydroxyl group prior to conjugation. It can nevertheless participate in the alternative phase II pathway by directly reducing sulfate- or glucuronide-conjugated androgens (PubMed : 19218247). In vitro can efficiently catalyze bidirectional conversion between ketosteroids and hydroxysteroids using NADPH/NADP(+) or NADH/NAD(+) as cofactors. In vivo however, the reductase activity prevails since the major reducing cofactor NADPH inhibits NAD(+)-dependent oxidase activity (PubMed : 14672942).
See full target information AKR1C1
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Journal of neuroinflammation 22:74 PubMed40069860

2025

Inhibition of histone deacetylase 6 alleviates neuropathic pain via direct regulating post-translation of spinal STAT3 and decreasing downstream C-C Motif Chemokine Ligand 7 synthesis.

Applications

Unspecified application

Species

Unspecified reactive species

Zhexi Chi,Bo Lu,Rongjun Liu,Chen Pan,Bo Meng,Xiuzhong Xing,Hui Yuan,Xuewei Wu,Yushan Chen,Yuxuan Ren,Wenwei Wu,Mengmeng Miao,Junping Chen,Xiaowei Chen
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com